Given the diversity of our agency's areas of competence, the various technical and scientific expertise must be present, and consolidated both internally and externally. This must be done through strictly defined, transparent and secure partnerships. This explains the absolute necessity of cooperative links between competent authorities, whether national, European or even global.
The strengthening and expansion of interaction mechanisms with our partners is one of the major achievements since the creation of the FAMHP.
The FAMHP interacts with many partners: patients, healthcare professionals, university and research centres, the industry, competent authorities and policy makers in the Member States and the EU institutions.
Given its role in protecting public health, the FAMHP believes it is necessary to maintain a genuine, open and constructive dialogue with all partners, not only within official institutions such as the Consultative Committee, but also via consultation platforms or other structures that provide an ideal framework for such a dialogue.
The FAMHP works with academia, the pharmaceutical and other relevant industries, healthcare professionals and other national, European and global bodies, as well as political leaders, to provide patients and citizens with the medicines and healthcare products they need and to help them make good use of them.
European cooperation
- EMA
National competent authorities, including the FAMHP, cooperate closely with the European Medicines Agency (EMA) within a structured European regulatory framework. This cooperation is based on shared responsibilities, mutual trust, and the pooling of scientific and regulatory expertise to support the lifecycle of medicines in the European Union. By contributing to joint assessments, coordinated decision-making, and continuous information exchange, national authorities and the EMA work together to ensure consistent regulatory standards, safeguard public health, and promote a harmonised approach to the evaluation, authorisation and supervision of medicinal products across Europe. - HMA
Within the Heads of Medicines Agencies (HMA) network, our role is to actively contribute to strategic collaboration among European medicines authorities. Through participation in HMA activities, we support alignment on regulatory policies, foster convergence of practices, and promote efficient cooperation between national agencies. The HMA framework enables collective reflection on emerging challenges, innovation and system-wide improvements, ensuring that national perspectives are integrated into a coherent and forward-looking European medicines regulatory system. - EMRN and Global Regulatory Cooperation
The European Medicines Regulatory Network (EMRN) embraces and actively supports cooperation with regulatory authorities in third countries. This collaboration aims to strengthen global regulatory systems, promote mutual reliance, and enhance public health worldwide. For direct contact with other National Competent Authorities (NCAs) within the EMRN, please refer to the NCA Contact List on the HMA website.